In order to explore the benefit of combining MEK and IMPDH inhibitors in the context of an organism, we treated mice harboring xenografts of RAS-mutant colorectal carcinoma HCT15 with MEK inhibitor selumetinib and IMPDH inhibitor ribavirin, singly or in combination (Figure 4A). This evidence concerns the gene MAP2K7 and colorectal carcinoma.